| Zacks Company Profile for MediciNova, Inc. (MNOV : NSDQ) |
|
|
| |
| • Company Description |
| MEDICINOVA, INC. is a publicly-traded biopharmaceutical company focused on acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical need with a specific focus on the U.S. market. Through strategic alliances primarily with Japanesepharmaceutical companies, MediciNova holds rights to a diversified portfolio of clinical and preclinical product candidates, each of which MediciNova believes has a well-characterized and differentiated therapeutic profile, attractive commercial potential and patent assets having claims of commercially adequate scope. MediciNova's pipeline includes six clinical-stage compounds for the treatment of status asthmaticus, multiple sclerosis, asthma, interstitial cystitis, solid tumor cancers, Generalized Anxiety Disorder, preterm labor and urinary incontinence and twopreclinical-stage compounds for the treatment of thrombotic disorders. MediciNova will seek to monetize its other product candidates at key value inflection points.
Number of Employees: 13 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $1.23 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 63,919 shares |
| Shares Outstanding: (millions) |
| Market Capitalization: $ (millions) |
| Beta: 0.43 |
| 52 Week High: $2.55 |
| 52 Week Low: $1.13 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
-5.38% |
-7.05% |
| 12 Week |
-3.15% |
-12.03% |
| Year To Date |
-41.43% |
-46.85% |
|
|
|
|
| |
|
|
| |
| • General Corporate Information |
Officers
Yuichi Iwaki - Chairman of the Board of Directors; President and
Jason Kruger - Chief Financial Officer
Carolyn Beaver - Director
Nicole Lemerond - Director
Kazuko Matsuda - Director
|
|
Peer Information
MediciNova, Inc. (CORR.)
MediciNova, Inc. (RSPI)
MediciNova, Inc. (CGXP)
MediciNova, Inc. (BGEN)
MediciNova, Inc. (GTBP)
MediciNova, Inc. (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 58468P206
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 06/01/25
Next Expected EPS Date: 11/12/25
|
|
Share - Related Items
Shares Outstanding:
Most Recent Split Date: (:1)
Beta: 0.43
Market Capitalization: $ (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $-0.08 |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $-0.27 |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: 2.00 |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 11/12/25 |
|
|
|
| |
